自己免疫疾患は、免疫系が誤って体を攻撃する病気です。免疫系は、外来細胞と体細胞の違いを決定することができます。それは健康な細胞を攻撃する自己抗体と呼ばれるタンパク質を放出します。一部の自己免疫疾患は、単一の臓器にのみ影響を及ぼします。1型糖尿病などは膵臓に有害です。全身性エリテマトーデス（SLE）などの他の疾患は全身に影響を及ぼします。
世界の自己免疫疾患診断市場の規模は、2020年の41億ドルから2030年までに83億ドルに拡大し、CAGRは8.9％になると予測されます。自己免疫疾患の発生率の上昇、自己免疫疾患に対する意識の向上、自己免疫疾患の研究の増加によって、この業界は大幅な成長を遂げています。
目次
Contents
1. Executive Summary
2. Autoimmune Disease Diagnosis
2.1. AI for Drug Discovery Product Overview
2.2. Market Definition
2.3. Segmentation
2.4. Assumptions and Acronyms
3. Research Methodology
3.1. Research Objectives
3.2. Primary Research
3.3. Secondary Research
3.4. Forecast Model
3.5. Market Size Estimation
4. Average Pricing Analysis
5. Market Dynamics
5.1. Growth Drivers
5.2. Restraints
5.3. Opportunity
5.4. Trends
6. Recent Development, Policies & Regulatory Landscape
7. Risk Analysis
7.1. Demand Risk Analysis
7.2. Supply Risk Analysis
8. Autoimmune Disease Diagnosis Industry Analysis
8.1. Porters Five Forces
8.1.1. Threat of New Entrants
8.1.2. Bargaining Power of Suppliers
8.1.3. Threat of Substitutes
8.1.4. Rivalry
8.2. PEST Analysis
8.2.1. Political
8.2.2. Economic
8.2.3. Social
8.2.4. Technological
9. Global Autoimmune Disease Diagnosis Market
9.1. Market Size & forecast, 2019A-2030F
9.1.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10. Global Autoimmune Disease Diagnosis: Market Segmentation
10.1. By Regions
10.1.1. North America: (U.S. and Canada) By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.1.2. Latin America: (Brazil, Mexico, Argentina, Rest of Latin America) By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.1.3. Europe: (Germany, UK, France, Italy, Spain, BENELUX, NORDIC, Hungary, Poland, Turkey, Russia, Rest of Europe) By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.1.4. Asia-Pacific: (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia Pacific) By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.1.5. Middle East and Africa: (Israel, GCC, North Africa, South Africa, Rest of Middle East and Africa) By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.2. By Product: Market Share (2020-2030F)
10.2.1. Consumables and Assay Kits, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.2.2. Instruments, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.2.3. Others, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
11. By Test Type: Market Share (2020-2030F)
11.1. Autoantibodies & Immunologic Test, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
11.2. Inflammatory Markers Routine Laboratory Tests, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
11.3. Routine Laboratory Tests, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12. By Disease: Market Share (2020-2030F)
12.1. . RA Thyroiditis Scleroderma, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.2. SLE, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.3. Thyroiditis Scleroderma, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.4. Scleroderma, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
13. . By Type: Market Share (2020-2030F)
13.1. Systemic Autoimmune Disease Diagnostics, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
13.2. Localized Autoimmune Disease Diagnostics, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
14. . By End-users: Market Share (2020-2030F)
14.1. Hospitals, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
14.2. Clinical Labs, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
14.3. Others, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
15. Company Profile
15.1. Abbott (US)
15.1.1. Company Overview
15.1.2. Company Total Revenue (Financials)
15.1.3. Market Potential
15.1.4. Global Presence
15.1.5. Key Performance Indicators
15.1.6. SWOT Analysis
15.1.7. Product Launch
15.2. AESKU GROUP GMBH & CO. KG (Germany)
15.3. Thermo Fisher Scientific (US)
15.4. Danaher (US)
15.5. HYCOR Biomedical (US)
15.6. Siemens (Germany)
15.7. Inova Diagnostics (US)
15.8. Trinity Biotech (Ireland)
15.9. Bio-Rad (US)
15.10. GRIFOLS (Spain)
Consultant Recommendation
**The above-given segmentations and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.
